Iraqi Lipid Clinics Network

01/10/2026

Together We Can Change

17/04/2026

🌍📣 Important update for our community

The HoFH Awareness Day Toolkit is now available, with key messages in 18 languages to help raise awareness of this rare and severe condition worldwide.

💡 Whether you're a patient, caregiver, healthcare professional, or advocate, the toolkit makes it easier to share clear, consistent information and spark conversations in your own community.

📢 We’re also looking for volunteers to help us expand into even more languages. If you’d like to contribute, this is a meaningful way to support global awareness and ensure more people can access vital information about HoFH.
Send an email to [email protected]

🤝 Share it. Use it. Help it grow.

Together, we can make HoFH better understood, everywhere.




European Atherosclerosis Society (EAS) & Congress
International Atherosclerosis Society - IAS
Rare Diseases International
Global Heart Hub
Iraqi Lipid Clinics Network
Alliance for Cardiovascular Health (EACH)

17/12/2025

We are delighted to announce that Prof. Heribert Schunkert has been awarded the 2026 Anitschkow Prize for his pioneering work in the genetics of atherosclerosis and cardiovascular disease.

We warmly congratulate and look forward to his Anitschkow Lecture, titled “The interplay of genetics and modifiable risk in atherosclerosis“, which will be presented during the EAS Congress Opening Ceremony on 24 May in Athens, Greece.

Read more about Professor Schunkert and his achievements here: https://eas.to/Anitschkow2026

17/12/2025

🚨 Fellowship Winner Highlight! 🚨

Based out of Ethiopia, Bisrat Demeke Shiferaw, MD, MPH, will be investigating Lipoprotein(a) as a cardiovascular risk marker in cardiac patients at the Hospital of Pisa.

17/12/2025

It's !

For the third lecture highlight, hear from Wolfgang Koenig, MD, as he discusses soluble markers and fat attenuation index.

Watch to learn more: https://bit.ly/43Sx2ch

17/12/2025

17/12/2025

The European Commission has officially published the - the first-ever comprehensive strategy to tackle the EU’s leading cause of death and disability, which reflects years of advocacy and collaboration across the European Alliance for Cardiovascular Health.

Now, another step lies ahead. We must act to ensure smooth adoption at the national level addressing local conditions and lived experience.

Learn more:
🇪🇺 Communication from the Commission on an EU Cardiovascular Health Plan: The Safe Hearts Plan - https://health.ec.europa.eu/publications/communication-eu-cardiovascular-health-plan-safe-hearts-plan_en
🇪🇺 Factsheet: The EU Safe Hearts Plan - https://ec.europa.eu/commission/presscorner/detail/en/fs_25_3075
🇪🇺 Questions and answers on the EU Safe Hearts Plan - https://ec.europa.eu/commission/presscorner/detail/en/qanda_25_3080

02/12/2025

🚨Dr.Khaled Abdel Sattar Al-Jumaili,
an interventional cardiologist, director of Baghdad adult Lipid Clinic
Al-Numan Hospital/Baghdad_Al-A'dhamiyah
International Atherosclerosis Society - IAS
European Atherosclerosis Society (EAS) & Congress
FH Europe - The European FH Patient Network

02/12/2025

For the first time globally, approves the use of Lojuxta for the treatment of children aged 5 years and older with Homozygous Familial Hypercholesterolemia (HoFH)
https://www.sfda.gov.sa/en/news/5194356

02/12/2025

للمرة الأولى عالميًا…
هيئة تعتمد استخدام "لوجكستا" لعلاج الأطفال المصابين بفرط كوليسترول الدم العائلي المتماثل من عمر 5 سنوات فأكثر.
https://www.sfda.gov.sa/ar/news/5194356